Alyx Arnett

1 month ago | sleepreviewmag.com | Alyx Arnett

For the first time, investigational treatments for narcolepsy type 1 (NT1) are targeting the disorder’s root cause: the loss of orexin-producing neurons. Unlike the symptom-based therapies on the market today, these candidates aim to mimic orexin signaling, offering a potentially disease-modifying approach. Some are also being evaluated for narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).

2 months ago | sleepreviewmag.com | Alyx Arnett

Wearable sleep rings are gaining ground, thanks to their comfort, simplicity, and growing clinical utility. US Food and Drug Administration (FDA)-cleared rings are being used not only for diagnostic sleep testing but also for longitudinal monitoring, while consumer rings drive more attention to sleep health. Companies like SleepImage and Belun Technology market rings cleared for diagnosing obstructive sleep apnea and evaluating sleep stages.

Mar 3, 2025 | sleepreviewmag.com | Alyx Arnett

Treating sleep apnea with a neurostimulator, such as Inspire for obstructive sleep apnea (OSA) or remedē for central sleep apnea (CSA), requires much more than one clinic visit. Steps include identifying a candidate, scheduling and undergoing implantation, activating the device, and titrating it—all before finally having the potential for optimal nightly use. Delays can occur at any stage, prolonging the process and leaving patients untreated.

Feb 26, 2025 | sleepreviewmag.com | Alyx Arnett

Sleep specialists can increase their role in the early detection of cardiac comorbidities in sleep apnea patients. Sleep Review’s Cardiology-Sleep Solutions column shares new technologies that can help. Email [email protected] with solutions you’d like to see featured here. Electrocardiogram (ECG) is a standard channel during in-lab polysomnography (PSG) but is generally absent from home sleep testing (HST) devices.

Dec 13, 2024 | sleepreviewmag.com | Alyx Arnett

Summary: The European Medicines Agency (EMA) has determined that Eli Lilly’s Mounjaro (tirzepatide), approved for weight management, does not require a separate indication for treating obstructive sleep apnea (OSA) in adults with obesity. Clinical data from two studies showed Mounjaro improves OSA symptoms by reducing weight. However, the EMA concluded these benefits are already covered under its existing approval for obesity treatment.